Difference between revisions of "Dinutuximab (Unituxin)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Intravenous chemotherapy" to "Category:Intravenous medications") |
m (→Also known as) |
||
Line 12: | Line 12: | ||
==Also known as== | ==Also known as== | ||
− | Ch14.18, MOAB Ch14.18, monoclonal antibody Ch14.18 | + | *'''Code names:''' Ch14.18, MOAB Ch14.18, monoclonal antibody Ch14.18 |
+ | *'''Brand name:''' Unituxin | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
− | |||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
Revision as of 02:17, 28 November 2017
Mechanism of action
From the NCI drug dictionary: A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.
Route: IV
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
History of changes in FDA indication
- 3/10/2015: Initial FDA approval "in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy."
Also known as
- Code names: Ch14.18, MOAB Ch14.18, monoclonal antibody Ch14.18
- Brand name: Unituxin